Moleculin Biotech, Inc.(MBRX)Earnings, Financials & Key Ratios
MBRX•NASDAQ
$2.48
$29M mkt cap·Price updated May 6, 2026
AboutMoleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.Show more
- Revenue$0
- EBITDA-$25M+5.7%
- Net Income-$34M-54.2%
- EPS (Diluted)-28.42+82.0%
- ROE-319.85%-135.5%
- ROIC-441.49%+41.7%
- Debt/Equity0.01-81.5%
MBRX Key Insights
Moleculin Biotech, Inc. (MBRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MBRX Price & Volume
Moleculin Biotech, Inc. (MBRX) stock price & volume — 10-year historical chart
Loading chart...
MBRX Growth Metrics
Moleculin Biotech, Inc. (MBRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-879.76%
Return on Capital
10 Years-84.59%
5 Years-94.14%
3 Years-127.21%
Last Year-187.07%
MBRX Peer Comparison
Moleculin Biotech, Inc. (MBRX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SNDX | 1.82B | 20.65 | -6.28 | 6.28% | -112.01% | -256.66% | 5.36 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ALDX | 104.68M | 1.74 | -1.85 | -87.71% | 0.22 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 CRIS | 81.2M | 0.62 | -1.06 | -13.43% | -80.29% | -138.81% | 0.30 |
Compare MBRX vs Peers
Moleculin Biotech, Inc. (MBRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MBRX Income Statement
Moleculin Biotech, Inc. (MBRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 18K | 68K | 185K | 0 | 0 | 0 | 0 | 0 | 90K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -18K▲ 0% | -68K▼ 277.8% | -185K▼ 172.1% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -90K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -192.11% | -277.78% | -172.06% | 100% | - | - | - | - | - |
| Operating Expenses | 8.65M | 15.03M | 17.34M | 19.74M | 22.97M | 30.64M | 29.63M | 26.64M | 25.1M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.09M | 5.3M | 6.33M | 6.79M | 8.39M | 11.54M | 10.02M | 8.79M | 9.12M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 4.54M | 9.73M | 11.01M | 12.76M | 14.42M | 18.97M | 19.49M | 17.73M | 15.89M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 18K | -40K | 0 | 200K | 164K | 130K | 127K | 126K | 90K |
| Operating Income | -8.65M▲ 0% | -15.03M▼ 73.6% | -17.52M▼ 16.6% | -19.74M▼ 12.7% | -22.97M▼ 16.3% | -30.64M▼ 33.4% | -29.63M▲ 3.3% | -26.64M▲ 10.1% | -25.1M▲ 5.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -122.83% | -73.64% | -16.63% | -12.66% | -16.34% | -33.4% | 3.29% | 10.09% | 5.77% |
| EBITDA | -8.63M | -14.96M | -17.34M | -19.54M | -22.8M | -30.51M | -29.5M | -26.52M | -25.01M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -122.72% | -73.21% | -15.93% | -12.71% | -16.69% | -33.79% | 3.3% | 10.13% | 5.66% |
| D&A (Non-Cash Add-back) | 18K | 68K | 185K | 200K | 164K | 130K | 127K | 126K | 90K |
| EBIT | -8.49M | -15.06M | -13.43M | -19.74M | -22.97M | -30.64M | -29.63M | -26.64M | -25.1M |
| Net Interest Income | 0 | 0 | 13K | 13K | 306K | 240K | 1.37M | 550K | 105K |
| Interest Income | 0 | 0 | 13K | 13K | 306K | 240K | 1.37M | 550K | 105K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.15M | 3.15M | 4.09M | 2.39M | 7.07M | 1.61M | -138K | 4.88M | -8.46M |
| Pretax Income | -9.8M▲ 0% | -11.88M▼ 21.1% | -13.43M▼ 13.1% | -17.36M▼ 29.2% | -15.89M▲ 8.4% | -29.02M▼ 82.6% | -29.77M▼ 2.6% | -21.76M▲ 26.9% | -33.56M▼ 54.2% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | -229K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 1.7% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -9.8M▲ 0% | -11.88M▼ 21.1% | -13.21M▼ 11.2% | -17.36M▼ 31.4% | -15.89M▲ 8.4% | -29.02M▼ 82.6% | -29.77M▼ 2.6% | -21.76M▲ 26.9% | -33.56M▼ 54.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -149.72% | -21.12% | -11.19% | -31.43% | 8.42% | -82.62% | -2.56% | 26.89% | -54.21% |
| Net Income (Continuing) | -9.8M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -21.76M | -33.56M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1188.00▲ 0% | -1031.50▲ 13.2% | -729.50▲ 29.3% | -661.00▲ 9.4% | -221.75▲ 66.5% | -380.50▼ 71.6% | -376.75▲ 1.0% | -158.00▲ 58.1% | -28.42▲ 82.0% |
| EPS Growth % | -32.15% | 13.17% | 29.28% | 9.39% | 66.45% | -71.59% | 0.99% | 58.06% | 82.01% |
| EPS (Basic) | -1188.00 | -1031.50 | -729.50 | -661.00 | -221.75 | -380.50 | -376.75 | -158.00 | -28.42 |
| Diluted Shares Outstanding | 8.25K | 11.51K | 18.1K | 26.25K | 71.67K | 76.28K | 79.02K | 137.72K | 11.85M |
| Basic Shares Outstanding | 8.25K | 11.51K | 18.1K | 26.25K | 71.67K | 76.28K | 79.02K | 137.72K | 11.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
MBRX Balance Sheet
Moleculin Biotech, Inc. (MBRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.3M | 7.97M | 13.48M | 17.2M | 72.5M | 45.6M | 26.27M | 5.19M | 9.69M |
| Cash & Short-Term Investments | 7.71M | 7.13M | 10.73M | 15.17M | 70.9M | 43.15M | 23.55M | 4.28M | 8.88M |
| Cash Only | 7.71M | 7.13M | 10.73M | 15.17M | 70.9M | 43.15M | 23.55M | 4.28M | 8.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 56K | 11K | 1K | 45K | 0 | 0 | 0 | 7K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 784K | 2.39M | 1.45M | 486K | 823K | 644K | 351K | 801K |
| Total Non-Current Assets | 11.18M | 11.61M | 11.75M | 11.96M | 11.59M | 11.83M | 11.94M | 11.73M | 12.44M |
| Property, Plant & Equipment | 33K | 463K | 603K | 685K | 445K | 678K | 796K | 583K | 314K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M | 11.15M |
| Long-Term Investments | 0 | 0 | 0 | 129K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 978K |
| Total Assets | 19.48M▲ 0% | 19.59M▲ 0.5% | 25.23M▲ 28.8% | 29.16M▲ 15.6% | 84.09M▲ 188.4% | 57.42M▼ 31.7% | 38.22M▼ 33.4% | 16.93M▼ 55.7% | 22.13M▲ 30.7% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 18.85% | 0.52% | 28.85% | 15.55% | 188.37% | -31.71% | -33.45% | -55.71% | 30.73% |
| Total Current Liabilities | 2.21M | 3.88M | 3.57M | 2.92M | 3.62M | 4.82M | 6.82M | 5.36M | 6.85M |
| Accounts Payable | 810K | 1.25M | 2.15M | 1.13M | 1.36M | 2.1M | 2.5M | 2.03M | 3.51M |
| Days Payables Outstanding | 16.43K | 6.69K | 4.25K | - | - | - | - | - | 14.23K |
| Short-Term Debt | 0 | 0 | 103K | 118K | 96K | 0 | 0 | 0 | 137K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.16M | 2.29M | 878K | 1.25M | 1.56M | 0 | 0 | 0 | 3.21M |
| Current Ratio | 3.75x | 2.06x | 3.78x | 5.89x | 20.02x | 9.46x | 3.86x | 0.97x | 1.41x |
| Quick Ratio | 3.75x | 2.06x | 3.78x | 5.89x | 20.02x | 9.46x | 3.86x | 0.97x | 1.41x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 150K | 1.44M | 6.09M | 8.35M | 1.48M | 412K | 5.33M | 5.59M | 266K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 222K |
| Capital Lease Obligations | 0 | 0 | 276K | 159K | 63K | 335K | 474K | 358K | 222K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 150K | 1.44M | 5.82M | 8.19M | 1.41M | 77K | 4.86M | 5.23M | 44K |
| Total Liabilities | 2.37M | 5.31M | 9.66M | 11.27M | 5.1M | 5.23M | 12.14M | 10.95M | 7.12M |
| Total Debt | 0 | 0 | 379K | 277K | 159K | 451K | 574K | 478K | 222K |
| Net Debt | -7.71M | -7.13M | -10.36M | -14.9M | -70.74M | -42.69M | -22.98M | -3.8M | -8.66M |
| Debt / Equity | - | - | 0.02x | 0.02x | 0.00x | 0.01x | 0.02x | 0.08x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 17.12M▲ 0% | 14.27M▼ 16.6% | 15.57M▲ 9.1% | 17.89M▲ 14.9% | 78.99M▲ 341.6% | 52.19M▼ 33.9% | 26.07M▼ 50.0% | 5.98M▼ 77.1% | 15.01M▲ 151.0% |
| Equity Growth % | 14.42% | -16.63% | 9.1% | 14.89% | 341.57% | -33.93% | -50.04% | -77.07% | 150.98% |
| Book Value per Share | 2074.15 | 1239.64 | 860.37 | 681.36 | 1102.19 | 684.22 | 329.94 | 43.41 | 1.27 |
| Total Shareholders' Equity | 17.12M | 14.27M | 15.57M | 17.89M | 78.99M | 52.19M | 26.07M | 5.98M | 15.01M |
| Common Stock | 21K | 29K | 46K | 69K | 29K | 29K | 33K | 3K | 3K |
| Retained Earnings | -14.48M | -26.36M | -39.56M | -56.92M | -72.81M | -101.83M | -131.6M | -153.37M | -206M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 35K | 31K | 65K | 41K | 12K | -9K | -41K | 10K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MBRX Cash Flow Statement
Moleculin Biotech, Inc. (MBRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.32M | -12.2M | -17.2M | -17.77M | -18.95M | -27.64M | -24.1M | -23.86M | -22.73M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -94.53% | -66.62% | -40.93% | -3.33% | -6.64% | -45.84% | 12.8% | 0.99% | 4.72% |
| Net Income | -9.8M | -11.88M | -13.21M | -17.36M | -15.89M | -29.02M | -29.77M | -21.76M | -33.56M |
| Depreciation & Amortization | 18K | 68K | 199K | 200K | 164K | 130K | 127K | 126K | 90K |
| Stock-Based Compensation | 707K | 1.14M | 1.54M | 1.68M | 2.37M | 2.27M | 1.98M | 1.73M | 1.66M |
| Deferred Taxes | -1.39M | 0 | 0 | -2.34M | -6.73M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.6M | -3.15M | -3.59M | 85K | 96K | -1.24M | 1.94M | -4.18M | 8.52M |
| Working Capital Changes | 542K | 1.61M | -2.14M | -41K | 1.04M | 224K | 1.62M | 231K | 555K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 411K | 436K | 907K | -1.02M | 235K | 731K | 403K | -468K | 1.33M |
| Cash from Investing | -28K | -417K | -51K | -374K | -19K | -67K | -124K | -13K | 0 |
| Capital Expenditures | -28K | -417K | -52K | -376K | -19K | -67K | -124K | -13K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 2K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 10.06M | 12.04M | 20.85M | 22.55M | 74.72M | -23K | 4.65M | 4.63M | 27.28M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | -23K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -104K |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -23K | 0 | 0 | 0 |
| Other Financing | 3.99M | 20K | 1.56M | -12K | 40K | 0 | 485K | -25K | 96K |
| Net Change in Cash | 2.71M▲ 0% | -580K▼ 121.4% | 3.6M▲ 720.9% | 4.44M▲ 23.2% | 55.73M▲ 1155.7% | -27.76M▼ 149.8% | -19.59M▲ 29.4% | -19.27M▲ 1.6% | 4.6M▲ 123.9% |
| Free Cash Flow | -7.35M▲ 0% | -12.62M▼ 71.7% | -17.25M▼ 36.7% | -18.15M▼ 5.2% | -18.97M▼ 4.5% | -27.71M▼ 46.1% | -24.23M▲ 12.6% | -23.88M▲ 1.4% | -22.73M▲ 4.8% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -94.17% | -71.65% | -36.69% | -5.2% | -4.54% | -46.05% | 12.56% | 1.44% | 4.77% |
| FCF per Share | -890.83 | -1096.15 | -953.14 | -691.18 | -264.69 | -363.22 | -306.55 | -173.36 | -1.92 |
| FCF Conversion (FCF/Net Income) | 0.75x | 1.03x | 1.30x | 1.02x | 1.19x | 0.95x | 0.81x | 1.10x | 0.68x |
| Interest Paid | 0 | 5K | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 21K | 19K | 24K | 15K | 0 | 0 | 0 | 0 |
MBRX Key Ratios
Moleculin Biotech, Inc. (MBRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -55.24% | -61.13% | -75.67% | -88.5% | -103.74% | -32.81% | -44.25% | -76.07% | -135.8% | -319.85% |
| Return on Invested Capital (ROIC) | -58.68% | -66.04% | -136.24% | -212.79% | -360.78% | -306.46% | -258.99% | -352.92% | -757.42% | -441.49% |
| Debt / Equity | 0.02x | - | - | 0.02x | 0.02x | 0.00x | 0.01x | 0.02x | 0.08x | 0.01x |
| Interest Coverage | -89.86x | - | - | - | - | - | - | - | - | - |
| FCF Conversion | 0.96x | 0.75x | 1.03x | 1.30x | 1.02x | 1.19x | 0.95x | 0.81x | 1.10x | 0.68x |
MBRX Frequently Asked Questions
Moleculin Biotech, Inc. (MBRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Moleculin Biotech, Inc. (MBRX) grew revenue by 0.0% over the past year. Growth has been modest.
Moleculin Biotech, Inc. (MBRX) reported a net loss of $23.9M for fiscal year 2025.
Dividend & Returns
Yes, Moleculin Biotech, Inc. (MBRX) pays a dividend with a yield of 0.35%. This makes it attractive for income-focused investors.
Moleculin Biotech, Inc. (MBRX) has a return on equity (ROE) of -319.8%. Negative ROE indicates the company is unprofitable.
Moleculin Biotech, Inc. (MBRX) had negative free cash flow of $22.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More MBRX
Moleculin Biotech, Inc. (MBRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates